Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia
- PMID: 26156087
- PMCID: PMC4496870
- DOI: 10.1186/s40478-015-0216-0
Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia
Abstract
Transthyretin/TTR gene mutations usually cause systemic amyloidotic diseases. Few TTR variants preferentially affect the central nervous system, manifesting as oculoleptomeningeal amyloidosis. Patients with TTR meningovascular amyloidosis often show dementia, however the neuropathologic features of dementia in these cases have not been elucidated. We report the neuropathologic findings from a brain autopsy of a 72-year-old man with the rare Tyr69His (Y69H) TTR gene variant, dementia and ataxia. Severe amyloid deposits were observed in the leptomeninges and in a subpial and subependymal distribution. Mass spectrometry analysis demonstrated that the amyloid deposits were comprised of over 80 % of the variant TTR. TTR was undetectable by mass spectrometry in the neocortex subjacent to the subpial amyloid deposits. Subpial TTR amyloid deposits were associated with brisk superficial reactive gliosis and siderosis in the neocortex and cerebellar cortex. Subependymal TTR amyloid deposits were associated with subjacent myelin pallor in the hippocampal outflow tract structures including the alveus, fimbria and fornix. Phospho-tau immunostains demonstrated transentorhinal-stage neurofibrillary degeneration (Braak stage II) which, in the absence of neocortical amyloid-beta and neuritic plaques, was indicative of primary age-related tauopathy (PART). However, distinctive phospho-tau aggregates were observed subjacent to the subpial TTR amyloid deposits in all regions of the neocortex, including the primary motor and striate cortices, suggesting a potential link between TTR amyloid and neocortical tauopathy. Our report reveals novel insights into the potential neuropathologic substrates of dementia in variant TTR amyloidosis that need to be investigated in larger autopsy series.
Figures
Similar articles
-
Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His.Neurology. 2003 May 27;60(10):1625-30. doi: 10.1212/01.wnl.0000065901.18353.ab. Neurology. 2003. PMID: 12771253
-
Transthyretin amyloidosis: a new mutation associated with dementia.Ann Neurol. 1997 Mar;41(3):307-13. doi: 10.1002/ana.410410305. Ann Neurol. 1997. PMID: 9066351
-
Transthyretin amyloidosis and superficial siderosis of the CNS.Neurology. 1999 Oct 22;53(7):1498-503. doi: 10.1212/wnl.53.7.1498. Neurology. 1999. PMID: 10534258
-
[Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis].Brain Nerve. 2013 Jul;65(7):831-42. Brain Nerve. 2013. PMID: 23832986 Review. Japanese.
-
Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant.Br Heart J. 1993 Aug;70(2):111-5. doi: 10.1136/hrt.70.2.111. Br Heart J. 1993. PMID: 8038017 Free PMC article. Review.
Cited by
-
Clinical considerations in early-onset cerebral amyloid angiopathy.Brain. 2023 Oct 3;146(10):3991-4014. doi: 10.1093/brain/awad193. Brain. 2023. PMID: 37280119 Free PMC article. Review.
-
Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.Int J Mol Sci. 2020 Sep 28;21(19):7166. doi: 10.3390/ijms21197166. Int J Mol Sci. 2020. PMID: 32998442 Free PMC article.
-
Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.Ther Clin Risk Manag. 2020 Feb 21;16:109-123. doi: 10.2147/TCRM.S219979. eCollection 2020. Ther Clin Risk Manag. 2020. PMID: 32110029 Free PMC article. Review.
-
The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy.Int J Mol Sci. 2019 Dec 14;20(24):6319. doi: 10.3390/ijms20246319. Int J Mol Sci. 2019. PMID: 31847365 Free PMC article. Review.
-
Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.Mol Diagn Ther. 2020 Feb;24(1):49-59. doi: 10.1007/s40291-019-00434-w. Mol Diagn Ther. 2020. PMID: 31701435 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous